ERLEADA(r) (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

Source :: Plus Company Updates. October 3, 2024
Publication Year :: 2024
Abstract: LISBON, Portugal: Johnson & Johnson has issued the following news release: Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA(r) (apalutamide) [...]

Subjects :: Johnson & Johnson
United States. Food and Drug Administration
Erleada (Medication) -- Comparative analysis
Care and treatment
Comparative analysis
Patient outcomes
Enzalutamide -- Comparative analysis
Medical research -- Comparative analysis
Prostate cancer -- Patient outcomes -- Care and treatment
Pharmaceutical industry -- Comparative analysis
Cancer metastasis -- Care and treatment -- Patient outcomes
Apalutamide -- Comparative analysis
Medicine, Experimental -- Comparative analysis
Metastasis -- Care and treatment -- Patient outcomes

Tools